Special Issue

Pharmacology of Glaucoma

Message from the Guest Editors

Glaucoma, an ocular condition characterized by elevated intraocular pressure (IOP), is one of the leading causes of irreversible blindness. Progressive loss of retinal ganglion cells (RGCs) and degeneration of optic nerve axons constitute the pathological hallmarks of glaucoma. IOP due to dysfunction of trabecular meshwork (TM) is considered to be a predominant risk factor for glaucoma. Currently, lowering of IOP has been demonstrated to reduce the progression of vision loss and is a mainstay of treatment for all types of glaucoma. Strategies used to lower IOP include drugs, lasers, or surgery. However, most physicians and patients use drug therapy as the first treatment strategy. This Special Issue of the Journal of Pharmaceuticals aims to highlight recent advances in the pharmacology of current glaucoma treatments, which could contribute to the easier, safer, and more effective management of glaucoma.

Guest Editors

Dr. Elie Beit-Yannai

Clinical Biochemistry and Pharmacology Department, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel

Prof. Dr. Ponugoti Vasantha Rao

Department of Ophthalmology, Duke University School of Medicine, Durham, NC 27710, USA

Deadline for manuscript submissions

closed (15 July 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/130681

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

